Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Double-blind, Randomized, 8-week Placebo-controlled, and 16-week Open-label Extension Study Investigating the Safety, Pharmacokinetics and Pharmacodynamics of SAR100842 Given Orally to Patients With Diffuse Cutaneous Systemic Sclerosis

NCT01651143 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT01651143
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01651143 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Double-blind, Randomized, 8-week Placebo-controlled, and 16-week Open-label Extension Study Investigating the Safety, Pharmacokinetics and Pharmacodynamics of SAR100842 Given Orally to Patients With Diffuse Cutaneous Systemic Sclerosis
Lead sponsor
Sanofi
Phase
Phase 2
Overall status
Completed
Start date
January 31, 2013
Completion date
April 30, 2014
Enrollment
32 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

systemic sclerosis